Catherine C. Y. Chang

Dr. Catherine C. Y. Chang

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 1993 in Journal of Biological Chemistry
Verified
Journal Article
Open access
CCCatherine C. Y. Chang
Catherine C. Y. Chang
HHH.Y. Huh
H.Y. Huh
KCK.M. Cadigan
K.M. Cadigan
TCT.Y. Chang
T.Y. Chang
Accumulation of cholesterol esters as cytoplasmic lipid droplets within macrophages and smooth muscle cells is a characteristic feature of early lesions of atherosclerotic plaque. Intracellularly, an essential element in forming cholesterol ester from cholesterol is the enzyme acyl-coenzyme A:cholesterol acyltransferase (ACAT). ACAT is a membrane protein located in the endoplasmic reticulum. The ACAT protein has never been purified to homogeneity, and no antibodies directed against ACAT have been reported. The gene(s) encoding this enzyme had not been isolated. This laboratory had previously reported the isolation of Chinese hamster ovary cells expressing human ACAT activity. From DNAs of these cells, we have cloned a 1.2-kb exonic human genomic DNA. This led to the eventual cloning of a 4-kb cDNA clone (K1) from a human macrophage cDNA library. Transfection of K1 in ACAT-deficient mutant Chinese hamster ovary cells complemented the mutant defect and resulted in the expression of human ACAT activity. K1 contained an open reading frame of 1650 bp encoding an integral membrane protein of 550 amino acids. Protein homology analysis showed that the predicted K1 protein shared homologous peptide sequences with other enzymes involved in the catalysis of acyl adenylate formation followed by acyl thioester formation and acyl transfer. These results indicate that K1 encodes a structural gene for ACAT. The cDNA reported here should facilitate future molecular studies on ACAT.

1 July 2015 in The Journal of Steroid Biochemistry and Molecular Biology
Verified
Journal Article
Closed access
MRMaximillian A. Rogers
Maximillian A. Rogers
JLJay Liu
Jay Liu
BSBao-Liang Song
Bao-Liang Song
BLBo-Liang Li
Bo-Liang Li
CCCatherine C. Y. Chang
Catherine C. Y. Chang
TCTA YUAN CHANG
TA YUAN CHANG

1 December 2017 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
TCTA YUAN CHANG
TA YUAN CHANG
YYYoshio Yamauchi
Yoshio Yamauchi
MHMazahir T. Hasan
Mazahir T. Hasan
CCCatherine C. Y. Chang
Catherine C. Y. Chang
Alzheimer’s disease (AD) is the most common form of dementia in older adults. Currently, there is no cure for AD. The hallmark of AD is the accumulation of extracellular amyloid plaques composed of amyloid-β (Aβ) peptides (especially Aβ1-42) and neurofibrillary tangles, composed of hyperphosphorylated tau and accompanied by chronic neuroinflammation. Aβ peptides are derived from the amyloid precursor protein (APP). The oligomeric form of Aβ peptides is probably the most neurotoxic species; its accumulation eventually forms the insoluble and aggregated amyloid plaques. ApoE is the major apolipoprotein of the lipoprotein(s) present in the CNS. ApoE has three alleles, of which the Apoe4 allele constitutes the major risk factor for late-onset AD. Here we describe the complex relationship between ApoE4, oligomeric Aβ peptides, and cholesterol homeostasis. The review consists of four parts: 1) key elements involved in cellular cholesterol metabolism and regulation; 2) key elements involved in intracellular cholesterol trafficking; 3) links between ApoE4, Aβ peptides, and disturbance of cholesterol homeostasis in the CNS; 4) potential lipid-based therapeutic targets to treat AD. At the end, we recommend several research topics that we believe would help in better understanding the connection between cholesterol and AD for further investigations.

25 March 2021 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
PDF file
MDMichael Tran Duong
Michael Tran Duong
INIlya M. Nasrallah
Ilya M. Nasrallah
DWDavid A. Wolk
David A. Wolk
CCCatherine C. Y. Chang
Catherine C. Y. Chang
TCTA YUAN CHANG
TA YUAN CHANG
Vascular contributions to cognitive impairment and dementia (VCID) are a common cause of cognitive decline, yet limited therapies exist. This cerebrovascular disease results in neurodegeneration via acute, chronic, local, and systemic mechanisms. The etiology of VCID is complex, with a significant impact from atherosclerosis. Risk factors including hypercholesterolemia and hypertension promote intracranial atherosclerotic disease and carotid artery stenosis (CAS), which disrupt cerebral blood flow and trigger ischemic strokes and VCID. Apolipoprotein E (APOE) is a cholesterol and phospholipid carrier present in plasma and various tissues. APOE is implicated in dyslipidemia and Alzheimer disease (AD); however, its connection with VCID is less understood. Few experimental models for VCID exist, so much of the present information has been drawn from clinical studies. Here, we review the literature with a focus on the clinical aspects of atherosclerotic cerebrovascular disease and build a working model for the pathogenesis of VCID. We describe potential intermediate steps in this model, linking cholesterol, atherosclerosis, and APOE with VCID. APOE4 is a minor isoform of APOE that promotes lipid dyshomeostasis in astrocytes and microglia, leading to chronic neuroinflammation. APOE4 disturbs lipid homeostasis in macrophages and smooth muscle cells, thus exacerbating systemic inflammation and promoting atherosclerotic plaque formation. Additionally, APOE4 may contribute to stromal activation of endothelial cells and pericytes that disturb the blood-brain barrier (BBB). These and other risk factors together lead to chronic inflammation, atherosclerosis, VCID, and neurodegeneration. Finally, we discuss potential cholesterol metabolism based approaches for future VCID treatment.

1 July 2015 in Neurobiology of Aging
Verified
Journal Article
Closed access
YSYohei Shibuya
Yohei Shibuya
ZNZhaoyang Niu
Zhaoyang Niu
EBElena Y. Bryleva
Elena Y. Bryleva
BHBrent T. Harris
Brent T. Harris
SMStephanie R. Murphy
Stephanie R. Murphy
TCTA YUAN CHANG
TA YUAN CHANG

18 May 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
CGChengcheng Guan
Chengcheng Guan
YNYange Niu
Yange Niu
SCSi-Cong Chen
Si-Cong Chen
YKYunlu Kang
Yunlu Kang
JWJing-Xiang Wu
Jing-Xiang Wu
LCLei Chen
Lei Chen
Sterol O-acyltransferase 1 (SOAT1) is an endoplasmic reticulum (ER) resident, multi-transmembrane enzyme that belongs to the membrane-bound O-acyltransferase (MBOAT) family. It catalyzes the esterification of cholesterol to generate cholesteryl esters for cholesterol storage. SOAT1 is a target to treat several human diseases. However, its structure and mechanism remain elusive since its discovery. Here, we report the structure of human SOAT1 (hSOAT1) determined by cryo-EM. hSOAT1 is a tetramer consisted of a dimer of dimer. The structure of hSOAT1 dimer at 3.5 Å resolution reveals that a small molecule inhibitor CI-976 binds inside the catalytic chamber and blocks the accessibility of the active site residues H460, N421 and W420. Our results pave the way for future mechanistic study and rational drug design targeting hSOAT1 and other mammalian MBOAT family members.